All Comments by Dave Morgan
- What Factors Make Amyloid Immunotherapy Successful?
- Cornucopia: LOADs of New Mouse Models Available
- In TRAILBLAZER, Plasma GFAP Falls, but NfL Continues to Rise
- Finally: Big Win on All Outcomes for Lecanemab in Phase 3 Topline Results
- Alzheimer disease neuropathology in a patient previously treated with aducanumab.
- Introducing … Sir John
- Plasma Aβ—First Sign of AD, But Tough to Measure Prospectively?
- On Donanemab, Plaques Plummet. Off Donanemab, They Stay Away
- In Phase 2, Donanemab Curbs Cognitive Decline in Early Alzheimer’s
- Microglia Inflammasome Stokes Tau Phosphorylation, Tangles
- Closing the Book on NSAIDs for Alzheimer’s Prevention
- Roche Pulls Plug on Two Phase 3 Trials of Crenezumab
- Inflammation Helps Microglia Clear Amyloid from AD Brains
- Astrocyte-derived TGF-β1 accelerates disease progression in ALS mice by interfering with the neuroprotective functions of microglia and T cells.
- Bapineuzumab Phase 3: Target Engagement, But No Benefit